About: Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria
Creator	Felger, Ingrid Corradin, Giampietro Céspedes, Nora Koepfli, Cristian Mueller, Ivo Nebie, Issa França, Camila Aré Valo-Herrera, Myriam Crates Herrera, Só Li, Connie Suen, Wai
Source	Medline; PMC
abstract	Protein α-helical coiled coil structures are known to induce antibodies able to block critical functions in different pathogens. In a previous study, a total of 50 proteins of Plasmodium vivax erythrocytic asexual stages containing α-helical coiled coil structural motifs were identified in silico, and the corresponding peptides were chemically synthesized. A total of 43 peptides were recognized by naturally acquired antibodies in plasma samples from both Papua New Guinea (PNG) and Colombian adult donors. In this study, the association between IgG antibodies to these peptides and clinical immunity was further explored by measuring total IgG antibody levels to 24 peptides in baseline samples from a longitudinal study of children aged 1–3 years (n = 164) followed for 16 months. Samples were reactive to all peptides tested. Eight peptides were recognized by >50% of individuals, whereas only one peptide had < 20% reactivity. Children infected at baseline were seropositive to 23/24 peptides. No significant association was observed between antibody titers and age or molecular force of infection, suggesting that antibody levels had already reached an equilibrium. There was a strong association between antibody levels to all peptides and protection against P. vivax clinical episodes during the 16 months follow-up. These results suggest that the selected coiled coil antigens might be good markers of both exposure and acquired immunity to P. vivax malaria, and further preclinical investigation should be performed to determine their potential as P. vivax vaccine antigens.
has issue date	2017-06-26(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0179863
bibo:pmid	28651021
has license	cc-by
sha1sum (hex)	75d78749fe0ededfadc860e8c5eb8562ddcc45f3
schema:url	https://doi.org/10.1371/journal.pone.0179863
resource representing a document's title	Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria
has PubMed Central identifier	PMC5484505
has PubMed identifier	28651021
schema:publication	PLoS One
resource representing a document's body	covid:75d78749fe0ededfadc860e8c5eb8562ddcc45f3#body_text
is schema:about of	named entity 'IMMUNE RESPONSE' named entity 'P. vivax' named entity 'equilibrium' named entity 'functions' named entity 'protein' named entity 'malaria' named entity '1-3' named entity 'COILED COIL' named entity 'MOTIFS' named entity 'HELICAL' named entity 'INDUCE' named entity 'IMMUNITY' named entity 'ANTIBODY TITERS' named entity 'CRITICAL' named entity 'ANTIGENS' named entity 'POTENTIAL' named entity 'PROTECTION' named entity 'STRONG' named entity 'VACCINE' named entity 'COLOMBIAN' named entity 'ACQUIRED IMMUNITY' named entity 'PATHOGENS' named entity 'COILED COIL' named entity 'YEARS' named entity 'PEPTIDES' named entity 'REACTIVITY' named entity 'PERFORMED' named entity 'MEASURING' named entity 'TOTAL IGG' named entity 'HELICAL' named entity 'AGE' named entity 'TOTAL' named entity 'CHEMICALLY' named entity 'ACQUIRED' named entity 'SUGGEST' named entity 'IGG ANTIBODY' named entity 'IDENTIFIED' named entity 'PLASMA' named entity 'ASEXUAL' named entity 'BASELINE' named entity 'CHILDREN' named entity 'AGED' named entity 'MOLECULAR' named entity 'FOLLOW-UP' named entity 'FOLLOWED' named entity 'DONORS' named entity 'VIVAX' named entity 'ASSOCIATION' named entity 'SELECTED' named entity 'ANTIBODY' named entity 'FORCE' named entity 'FUNCTIONS' named entity 'STAGES' named entity 'THEIR' named entity 'EQUILIBRIUM' named entity 'CONTAINING' named entity 'PEPTIDE' named entity 'MIGHT BE' named entity 'EPISODES' named entity 'VIVAX MALARIA' named entity 'PAPUA NEW GUINEA' named entity 'STRUCTURAL MOTIFS' named entity 'PREVIOUS' named entity 'ALPHA' named entity 'SAMPLES' named entity 'EXPOSURE' named entity 'BLOCK' named entity 'MARKERS' named entity 'LONGITUDINAL STUDY' named entity 'IN SILICO' named entity 'INFECTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software